A case report of paclitaxel administered to a patient with platinum-refractory ovarian cancer on long-term hemodialysis.
We present the second case of a patient with platinum-refractory ovarian cancer who was treated safely with paclitaxel while on hemodialysis. Paclitaxel was administered at 175 mg/m2 as a 24-hour intravenous infusion on a nondialysis day. The patient tolerated this therapy well with minimal toxic reactions except for total alopecia and myelosuppression, which was unremarkable. Paclitaxel may be used in patients receiving long-term hemodialysis in the same dose schedule as in patients with normal renal function.
Balat
O
O
University of Texas, M.D. Anderson Cancer Center, Houston, USA.
Kudelka
A P
AP
Edwards
C L
CL
Verschraegen
C
C
Mante
R
R
Kavanagh
J J
JJ
D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel / Q000627:therapeutic use*; D006435:Renal Dialysis
D000972:Antineoplastic Agents, Phytogenic; D017239:Paclitaxel